Movement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss

Market Focus07-29

On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.

The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.

The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121031859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121031859","market":"us","top_or_hot":-1,"title":"Movement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss","media":"Market Focus","content":"<p><p>On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.</p><p>The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.</p><p>The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-29 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.</p><p>The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.</p><p>The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1121031859","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121031859","pubTimestamp":1785323408,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.The movement was primarily driven by the company's Q2 earnings release. Teva...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"走势提醒|梯瓦制药盘前交易上涨 5.15%，尽管每股收益大幅下滑，第二季度收入仍超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121031859","isCrawlerRequest":true}